116 related articles for article (PubMed ID: 34055650)
1. Case Report:
Fan J; Liang H; Zhang X; Chen X; Duan X; Li L; He D; Wu K
Front Oncol; 2021; 11():683343. PubMed ID: 34055650
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Case Report:
Li Y; Li Y; Dong S; Chen J; Yang P; Li J
Front Oncol; 2022; 12():881896. PubMed ID: 35530336
[TBL] [Abstract][Full Text] [Related]
4. Isolated, PSMA-negative penile metastasis from castration resistant prostate adenocarcinoma, identified by FDG-PET.
Chau M; Swarbrick N; Lee S
Urol Case Rep; 2023 Jan; 46():102300. PubMed ID: 36568633
[TBL] [Abstract][Full Text] [Related]
5. Mesorectal Lymph Node Metastases as Index Lesion in
Leitsmann C; Schmid M; Sahlmann CO; Trojan L; Strauss A
Front Surg; 2021; 8():637134. PubMed ID: 33732729
[No Abstract] [Full Text] [Related]
6. A Case of Penile Metastasis from Prostate Cancer, Identified by
Gossili F; Langkilde NC; Zacho HD
Diagnostics (Basel); 2023 Jul; 13(15):. PubMed ID: 37568872
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
Hinsenveld FJ; Wit EMK; van Leeuwen PJ; Brouwer OR; Donswijk ML; Tillier CN; Vegt E; van Muilekom E; van Oosterom MN; van Leeuwen FWB; van der Poel HG
J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
9.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
10. A prospective intra-individual comparison of [
Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
[TBL] [Abstract][Full Text] [Related]
11. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
12. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
Koschel S; Murphy DG; Hofman MS; Wong LM
Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
[TBL] [Abstract][Full Text] [Related]
13. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of
Rahbar K; Afshar-Oromieh A; Seifert R; Wagner S; Schäfers M; Bögemann M; Weckesser M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2055-2061. PubMed ID: 30027419
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between
Thomas L; Balmus C; Ahmadzadehfar H; Essler M; Strunk H; Bundschuh RA
Pharmaceuticals (Basel); 2017 Jul; 10(3):. PubMed ID: 28758969
[TBL] [Abstract][Full Text] [Related]
16.
Oliveira JM; Gomes C; Faria DB; Vieira TS; Silva FA; Vale J; Pimentel FL
World J Nucl Med; 2017; 16(1):3-7. PubMed ID: 28217012
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
18. Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma.
Koerber SA; Boesch J; Kratochwil C; Schlampp I; Ristau J; Winter E; Zschaebitz S; Hofer L; Herfarth K; Kopka K; Holland-Letz T; Jaeger D; Hohenfellner M; Haberkorn U; Debus J; Giesel FL
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805971
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of [
Paymani Z; Rohringer T; Vali R; Loidl W; Alemohammad N; Geinitz H; Langsteger W; Beheshti M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32708097
[TBL] [Abstract][Full Text] [Related]
20.
Udovicich C; Perera M; Hofman MS; Siva S; Del Rio A; Murphy DG; Lawrentschuk N
Prostate Int; 2017 Dec; 5(4):125-129. PubMed ID: 29188197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
